About Our Team

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

The Mercy Story

The kernel of Mercy BioAnalytics was sown when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan. That young man was Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan with a degree in biomedical engineering, entered Harvard Medical School, and along the way became Paul’s adopted son. Through his studies at labs across Harvard and MIT, Joseph’s interest was piqued when he recognized the largest unmet need in oncology was the early detection of cancer.

As a young scientist comfortable with new concepts, such as nanotechnology and single cell analysis, Joseph developed the novel idea on which he founded Mercy BioAnalytics with Paul in 2018: using single extracellular vesicles for early cancer detection. The company leverages Paul’s business savvy and connections with Joseph’s scientific curiosity in its mission to improve the lives of patients suffering from cancer.

Paul and Joseph have gathered around them a stellar group of advisors and colleagues with decades of experience and success in cancer detection and diagnostics who share their mission.

Team Mercy

Paul Blavin

Paul Blavin

Co-Founder, Chief Executive Officer

Joseph Sedlak, MD PhD

Joseph Sedlak, MD PhD

Expected 2023

Co-Founder, Chief Scientific Officer

Laura Bortolin, PhD

Laura Bortolin, PhD

Co-Director of Research & Development

Daniel Salem, PhD

Daniel Salem, PhD

Co-Director of Research & Development

Emily Winn-Deen, PhD

Emily Winn-Deen, PhD

Sr. Vice President ofDiagnostics Strategy

Anthony Couvillon, PhD

Anthony Couvillon, PhD

Sr. Scientist, Head of Antibody Discovery

Daniel Gusenleitner, PhD

Daniel Gusenleitner, PhD

Head of Computational Biology

Claire Alexander BSN, MBA

Claire Alexander BSN, MBA

Vice President of Clinical Affairs

Ibukun Zabroski, Ph.D.

Ibukun Zabroski, Ph.D.

Scientist

Jennifer Shepard

Jennifer Shepard

Scientist

Chris Sedlak

Chris Sedlak

Research & Development Engineer

Britt Derrien

Britt Derrien

Executive Assistant

Since Mercy’s inception in April 2018, we have been inspired by the old African Proverb:

“If you want to go fast, go alone.
If you want to go far, go together.”

We are humbled and grateful to have locked arms with a world-class group of scientists, clinicians and diagnostic business leaders, all passionate and determined to save lives by detecting cancer early when it is most curable.

Board of Directors

Stanley Lapidus

Stanley Lapidus

Chairman

Paul Meister

Paul Meister

Sonja Hoel Perkins

Sonja Hoel Perkins

Paul Blavin

Paul Blavin

Joseph Sedlak

Joseph Sedlak

Strategic Advisors

Ted Snelgrove

Ted Snelgrove

Sr Executive Advisor

Barry Berger, MD

Barry Berger, MD

Chief Medical Advisor

Ellen Goldberg

Ellen Goldberg

Marketing

Floyd Taub, MD

Floyd Taub, MD

Sr Executive Advisor

Alberto Gutierrez, PhD

Alberto Gutierrez, PhD

Regulatory Affairs

Clinical Collaborators

Beth Karlan, MD

Beth Karlan, MD

Douglas Levine, MD

Douglas Levine, MD

Charles “Chip” Landen, MD

Charles “Chip” Landen, MD

Bo Rueda, PhD

Bo Rueda, PhD

Amy Bregar, MD

Amy Bregar, MD

World Leaders in Clinical Trials

World renowned advisors with over 100 years of combined experience designing and conducting the most prominent clinical trials for the early detection of cancer.

David Ransohoff, MD

David Ransohoff, MD

Steven Skates, PhD

Steven Skates, PhD

Christine Berg, MD

Christine Berg, MD

“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”

– Margaret Mead

Unparalleled Innovation.

Real collaboration.

Join Mercy BioAnalytics on our lifesaving mission to detect cancer early when it is most curable

ACCELERATING CLINICAL TRIALS

For pharmaceutical companies, Mercy Halo offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrollment, and companion diagnostic development to support commercialization of new drugs.

Mercy BioAnalytics works for companies who want to increase the chances of a drug’s success in clinical trials. Mercy Halo helps identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage.

The Mercy Way

We are on a mission to improve and save the lives of people across the globe through the early detection of cancer, when it is most curable. These principles, “The Mercy Way”, are our true north. They guide every decision we make.

saving lives

Saving lives guides our every decision

humility

Always lead with humility, empathy and compassion, never ego

data

Data and sound reasoning inform our decisions, not opinions, conventional wisdom or fear

seconds count

Every second counts

we are all us

There is no “us” and “them” – we are all “us”

yes before no

Yes before no

what is right

It’s not about WHO is right, it’s about WHAT is right

finding the way

Obsessed with finding a better way

believing is seeing

You’ll see it when you believe it

lead

Numbers and money follow, they never lead

Paul and Joseph, Mercy’s co-founders, are thrilled to dedicate 1/3 of the value of their investment in Mercy BioAnalytics to the establishment of the Mercy Foundation. The foundation supports life transformation for young people who need it the most and are least able to help themselves, focusing on those that have experienced foster care, homelessness, abandonment, abuse, neglect or incarceration. This legacy of serving the underserved is at the heart of our co-founder’s personal story.